Solo Practice Electronic Controlled Substance Prescribing Statistics

The adoption series

Electronic prescribing of controlled substances, commonly shortened to EPCS, is a narrower measure than ordinary electronic prescribing. It concerns controlled-substance prescriptions sent under federal and state requirements, including identity proofing, two-factor authentication, access controls, and audit functions. A physician who electronically prescribes routine medications is not necessarily an EPCS user.

ONC analyzed nationally representative National Electronic Health Records Survey data for office-based physicians who prescribed controlled substances. In 2017, 32% reported using EPCS. The estimate rose to 44% in 2019 and 71% in 2021. The underlying population is prescribers of controlled substances, not all physicians, all prescriptions, or all controlled-substance transactions.

Frequency adds another layer. ONC reported that 62% of physician prescribers in 2021 said they used EPCS often, compared with 37% in 2019. "Uses EPCS" and "often uses EPCS" answer different questions. A practice can have the technical capability but still use another permitted process for some prescriptions.

The dates describe survey years. They should not be presented as a current 2026 adoption rate. Mandates, vendor capabilities, state rules, federal policy, and practice behavior continued to change after each survey. The series is useful evidence of rapid adoption through 2021, not a live registry.

Solo and small-practice comparisons

Practice size was associated with EPCS use. In 2021, ONC estimated use among 62% of prescribers in one-physician practices and 64% in practices with two or three physicians. The corresponding estimates were 76% for practices with four to ten physicians and 82% for practices with eleven or more physicians. The report marks statistically significant comparisons against its reference category where appropriate.

This gap narrowed substantially over the survey series. In 2017, ONC estimated EPCS use among 23% of physicians in one-physician practices. The 2019 report estimated 30% among solo practitioners. These figures come from successive cross-sectional surveys, not from tracking the same solo physicians over time.

Ownership categories showed differences as well. In 2021, ONC estimated 63% EPCS use among prescribers in physician-owned practices, compared with 82% in hospital-owned practices and 90% in practices owned by an insurance company or corporation. Ownership and size overlap in real organizations. The descriptive estimates do not isolate ownership as the cause.

Specialty results also varied. ONC reported 79% use among primary care prescribers, 67% among surgical specialists, and 61% among medical specialists in 2021. A solo-practice comparison should not ignore specialty mix, controlled-substance prescribing frequency, geography, vendor, and local requirements.

What EPCS adoption does not prove

An adoption rate does not measure whether prescriptions are clinically appropriate. It does not measure diagnostic quality, medication selection, dose, monitoring, patient outcomes, diversion, or overdose. Those questions require different data and study designs.

Adoption also does not guarantee reliable transmission. A prescription can fail because of identity matching, pharmacy routing, network availability, data validation, or workflow error. A survey response about EPCS use does not count failed sends, pharmacy callbacks, cancellations, replacements, or time spent resolving exceptions.

EPCS and prescription drug monitoring program use are related but separate. A clinician may check a PDMP through an EHR, a state portal, or another connection. The 2021 ONC brief estimated that 78% of physician prescribers checked the PDMP before first prescribing a controlled substance to a patient. It also reported whether access occurred electronically through the EHR. Neither measure proves that every legally required check occurred.

Federal DEA rules establish a framework, while state law and payer or pharmacy policy may add requirements. This article does not determine which rules apply to a particular prescription. A practice should use current official guidance and qualified compliance advice.

A local measurement protocol

Start with eligibility. Define which clinicians are authorized to prescribe controlled substances and which prescription schedules and jurisdictions are in scope. Keep enrollment, identity proofing, credential status, token assignment, and access authorization in a controlled register. Do not place authentication secrets in an operational spreadsheet.

For utilization, count eligible controlled-substance prescriptions, successfully transmitted EPCS prescriptions, permitted non-electronic prescriptions, failed transmissions, cancellations, replacements, and pharmacy clarification contacts. Report both counts and rates. A high rate based on five prescriptions has different operational meaning from the same rate based on five hundred.

Define the clock for exceptions. Measure active handling time separately from elapsed time. An item waiting for a pharmacy or network is open but not under continuous staff work. Capture the reason code and final disposition instead of treating every exception as a user error.

Audit access periodically. The DEA rule addresses logical access controls and records. The practice should follow its written policies for approving, modifying, and removing permissions, with clinical and security oversight. Administrative staff can support documentation, but they should not receive prescribing authority through convenience or informal credential sharing.

Measure patient and pharmacy effects cautiously. A callback count may signal routing problems, unclear instructions, supply issues, insurance requirements, or clinical questions. Classify a sample before choosing an intervention. A before-and-after decline can show association, but it does not prove the technology caused the change if staffing, volume, vendor configuration, or prescribing mix also changed.

Methodology and limits

We reviewed ten federal sources covering the nationally representative survey estimates, DEA requirements, Medicare Part D standards, PDMP context, and public-health guidance. The ONC 2021 brief is the primary source for current figures in this review. Earlier ONC briefs provide the 2017 and 2019 comparison points.

Survey responses may contain recall and classification error. Estimates are weighted and have sampling uncertainty. The practice-size groups count physicians in a practice, not sites, staff, or prescription volume. Statistical association across size or ownership groups does not establish that size or ownership caused adoption.

Local rates should also disclose missing records and the observation window, because silent exclusions can make a workflow look more complete than it is. The conclusion is limited but useful. EPCS use increased sharply among office-based controlled-substance prescribers between 2017 and 2021, and solo-practice adoption remained below the estimates for larger groups in 2021. An independent practice should treat those figures as historical context, then measure its own eligible prescribers, prescriptions, exceptions, and controls under current law and policy.